Video

Second-Line Treatment of HER2+ mBC and Recent Data Updates

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Video Player is loading.
Current Time 0:00
Duration 8:42
Loaded: 0%
Stream Type LIVE
Remaining Time 8:42
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected